Response to: 'Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis' by Lee and Song
- PMID: 29440039
- DOI: 10.1136/annrheumdis-2017-212871
Response to: 'Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis' by Lee and Song
Keywords: corticosteroids; dmards (biologic); systemic vasculitis.
Conflict of interest statement
Competing interests: YN reports personal fees from Chugai as a consultant of the sponsor-initiated clinical trial (Chugai Pharmaceutical Co.) using tocilizumab for Takayasu arteritis; grants and personal fees from Chugai; grants and personal fees from Astellas, Pfizer, and MSD outside the submitted work; grants from Takeda, Otsuka, Bayer outside the submitted work; and personal fees from Daiichi Sankyo and Kowa Pharmaceutical Co. outside the submitted work.
Comment on
-
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).Ann Rheum Dis. 2018 Mar;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30. Ann Rheum Dis. 2018. PMID: 29191819 Free PMC article. Clinical Trial.
-
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis.Ann Rheum Dis. 2019 Jan;78(1):e9. doi: 10.1136/annrheumdis-2017-212838. Epub 2017 Dec 29. Ann Rheum Dis. 2019. PMID: 29288209 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
